Literature DB >> 26568012

Successful Management of Lupus Nephritis with High Titers of Myeloperoxidase Anti-Neutrophil Cytoplasmic Antibodies Using Tacrolimus.

Yoshikazu Abe1, Tomoaki Shima, Yasumori Izumi, Mineaki Kitamura, Hiroshi Yamashita, Yoshika Tsuji, Osamu Sasaki, Chie Maeda, Chieko Kawahara, Ai Torisu, Yuuki Kawaguchi, Hirokazu Kurohama, Masahiro Ito, Nozomi Iwanaga, Atsushi Kawakami, Toshiyuki Nakayama, Takashi Taguchi, Kiyoshi Migita.   

Abstract

A 63-year-old Japanese woman with a 30-year history of systemic lupus erythematosus developed macrohematuria and massive proteinuria after seroconversion of myeloperoxidase anti-neutrophil cytoplasmic antibodies (MPO-ANCA). A renal biopsy indicated focal proliferative lupus nephritis (class III A/C) with a fibrous crescent formation. Methylprednisolone pulse therapy (500 mg, 3 successive days) was administered because of progressive proteinuria. Steroid therapy did not suppress the progressive proteinuria; therefore, tacrolimus was added as an alternative immunosuppressive therapy, resulting in the improvement of proteinuria and renal impairment. This case report suggests that MPO-ANCA might play a pathogenic role in the exacerbation of immune-complex-type lupus nephritis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26568012     DOI: 10.2169/internalmedicine.54.4343

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

1.  Serum creatinine level and ESR values associated to clinical pathology types and prognosis of patients with renal injury caused by ANCA-associated vasculitis.

Authors:  Hongda Liang; Miaomiao Xin; Lei Zhao; Liqin Wang; Mingshu Sun; Jibo Wang
Journal:  Exp Ther Med       Date:  2017-10-16       Impact factor: 2.447

2.  Clinicopathologic characteristics and outcomes of lupus nephritis with positive antineutrophil cytoplasmic antibody.

Authors:  Shuai Wang; Jin Shang; Jing Xiao; Zhanzheng Zhao
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.